Birmingham Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Mov Disord. 2010 Nov 15;25(15):2649-53. doi: 10.1002/mds.23429.
Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.
比较不同药物治疗帕金森病（PD）方案的临床试验解释起来很复杂，原因是使用的剂量强度不同：左旋多巴和其他药物的高剂量可产生更好的症状控制效果，但也会产生更多的晚期并发症。为了解决这个问题，人们已经为抗帕金森病药物计算了转换因子，以获得总日剂量的左旋多巴等效剂量（LED）。LED 估计值存在差异，因此我们对报告 LED 的研究进行了系统回顾，以提供标准化公式。电子数据库和参考文献的手动搜索确定了 56 篇关于 LED 估计值的主要报告。提取数据并计算平均和模态 LED。这为每种药物生成了一个标准化的 LED，为在单一尺度上表示不同抗帕金森病药物方案的剂量强度提供了一个有用的工具。使用这些转换公式报告 LED 将提高报告的一致性，并有助于解释比较不同 PD 药物的临床试验。
